|

IBI362 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Innovent Biologics (Suzhou) Co. Ltd.2

Indications

  • Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)1
  • Heart Failure With Preserved Ejection Fraction (HFPEF)1
  • Heart Failure With Mildly Reduced Ejection Fraction1
  • Liver Disease1
  • Heart Disease1

Other2 trials

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Phase 3
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.